Skip to content
lifestyle.ideacrossing.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
HUTCHMED (China) Limited
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
June 11, 2026
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
May 25, 2026
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
May 23, 2026
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
May 22, 2026
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
April 29, 2026
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
March 22, 2026
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
March 9, 2026
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
March 6, 2026
HUTCHMED Reports 2025 Full Year Results and Business Updates
March 5, 2026
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
March 4, 2026
1
2
Next Page
→